Loss-of-function mutations in SPOP may lead to elevated levels of the HDAC6 oncoprotein, which could promote tumorigenesis and metastasis in CRC, highlighting the potential for targeted therapies aimed at this axis. This evidence concerns the gene HDAC6 and colorectal carcinoma.